Antitrust regulators shouldn’t clear Novo Holdings’ planned acquisition of Catalent, Roche CEO Thomas Schinecker said Wednesday, adding to the pressure that industry competitors appear to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.